Richard Webber, MD
Internal Medicine · Plattsburgh, NYNPI 1932279049
Payments from drug & device makers
Across 343 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$900
- AstraZeneca$615
- GSK$555
- Lilly USA, LLC$535
- Amgen$371
- plus $2K from 22 others
What the payments were for
- Food & beverage$6,003100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $1,363 |
| Novo Nordisk | 52 | $900 |
| AstraZeneca | 33 | $615 |
| GSK | 36 | $555 |
| Lilly USA, LLC | 31 | $535 |
| Amgen | 23 | $371 |
| Pfizer | 15 | $300 |
| Otsuka America Pharmaceutical, Inc. | 8 | $179 |
| Novartis | 10 | $174 |
| Boehringer Ingelheim | 6 | $138 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $115 |
| Abbott | 5 | $91 |
| Lundbeck LLC | 4 | $84 |
| Sanofi-aventis U.S. LLC | 5 | $83 |
| Baxter Healthcare | 2 | $81 |
| Johnson & Johnson | 3 | $71 |
| Astellas Pharma US Inc | 3 | $62 |
| Viatris Specialty LLC | 2 | $52 |
| Exact Sciences | 2 | $47 |
| Collegium Pharmaceutical, Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Merck | 2 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $13 |
How this compares
$6,015 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 153 | $224,788 |
| OzempicSemaglutide | 97 | $158,857 |
| TrulicityDulaglutide | 64 | $112,569 |
| JardianceEmpagliflozin | 45 | $73,149 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $55,816 |
| MounjaroTirzepatide | 23 | $43,527 |
| RybelsusSemaglutide | 26 | $39,869 |
| XareltoRivaroxaban | 24 | $39,570 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $28,058 |
| Humalog Kwikpen U-200Insulin Lispro | 27 | $25,598 |
| MyrbetriqMirabegron | 24 | $25,364 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $22,556 |
| FarxigaDapagliflozin Propanediol | 15 | $21,298 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $17,735 |
| Levothyroxine Sodium | 343 | $9,730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $300 | $224,788153 claims |
| Novo NordiskOzempic, Rybelsus | $900 | $198,726123 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $535 | $156,09687 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $555 | $91,814109 claims |
| Boehringer IngelheimJardiance | $138 | $73,14945 claims |
| Johnson & JohnsonXarelto | $71 | $39,57024 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $25,36424 claims |
| AstraZenecaFarxiga | $615 | $21,29815 claims |
| AbbVieSynthroid | $1,363 | $1,75439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Plattsburgh
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.